Abstract 2017P
Background
Small cell lung cancer (SCLC) is one of the most lethal forms of lung cancer, with a 5-year survival rate of approximately 7%. SCLC has been divided into limited stage (LS) and extensive stage (ES). For ES-SCLC the use of immunotherapy (IO) has been introduced in combination with platinum-based chemotherapy (CT), prolonging the overall survival of patients. However, only a small fraction of patients experience a durable clinical benefit from this approach, with no selection criteria able to predict clinical outcome. Here we hypothesize that different mutational profiles could be associated to clinical outcome of patients treated with CT-IO with respect to CT alone.
Methods
A case series of 88 ES-SCLC patients was enrolled. Tumor tissues of patients were analysed with a next-generation sequencing-based assay (Foundation One CDx), analysing 324 genes, selected gene rearrangements, microsatellite instability (MSI) and tumor mutational burden (TMB). Statistical analyses have been performed to study the correlation among clinical characteristics, mutational profiles and clinical outcome has been performed.
Results
For patients with available clinical information, 36 were treated with CT-IO and 50 with CT alone. The 65% of patients were male, and the 35% were female, median age was 71 (range 50-86) years old. The 36.2% of patients were former smokers whereas 53.75% were current smokers, while smoking habits were not available for 16 patients. The most frequently mutated genes were TP53 (98%), RB1 (80%), MLL2 (35%), NOTCH3 (16.2%), MLL (12.5%), RICTOR (8.8%), CDKN2A/B (7.3%), APC (7.3%), MYC (6.3%) and MYCL1 (6.3%). No rearrangements were detected in any patient. With regard to TMB, 25% of patients had low TMB (<6 mut/Mb), 65% of patients had intermediate TMB (6>20 mut/Mb), and 10% of patients had high TMB (>20 mut/Mb). MSI data was available for 67 patients, and all but one patients were stable. Survival analyses and correlation of clinical outcome with mutational profiles are still ongoing.
Conclusions
Our results suggest that a comprehensive genomic profile could help to predict clinical outcome of ES-SCLC patients treated with CT-IO.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1877P - Meaning-making in the re-entry phase: A qualitative focus group study with patients with breast cancer and melanoma
Presenter: Anna Visser
Session: Poster session 05
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05